Radavirsen performs well in early influenza trial

(Wiley) A phase 1 clinical trial published in the British Journal of Clinical Pharmacology found that radavirsen--an antisense oligomer that inhibits the production of certain influenza proteins -- is safe and well-tolerated in healthy individuals. Additional studies on radavirsen's potential as a treatment for influenza are warranted.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news